Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

Conditions

• Anaplastic Large Cell Lymphoma
• Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
• Recurrent Anaplastic Large Cell Lymphoma
• Recurrent Angioimmunoblastic T-Cell Lymphoma
• Recurrent Enteropathy-Associated T-Cell Lymphoma
• Recurrent Follicular Lymphoma
• Recurrent Hepatosplenic T-Cell Lymphoma
• Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma
• Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
• Recurrent Mycosis Fungoides
• Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Refractory Anaplastic Large Cell Lymphoma
• Refractory Angioimmunoblastic T-Cell Lymphoma
• Refractory Enteropathy-Associated T-Cell Lymphoma
• Refractory Follicular Lymphoma
• Refractory Hepatosplenic T-Cell Lymphoma
• Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
• Refractory Mycosis Fungoides
• Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
• Subcutaneous Panniculitis-Like T-Cell Lymphoma

Interventions

• BIOLOGICAL: Pembrolizumab
• DRUG: Pralatrexate

Sponsor

City of Hope Medical Center

Collaborators

• [object Object]